Back
NewAmsterdam Pharma Co NV 10K Form
Sell
43
NAMS
NewAmsterdam Pharma Co NV
Last Price:
$25.92
Seasonality Move:
41.96%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive NAMS News And Ratings
See the #1 stock for the next 7 days that we like better than NAMS
NAMS Financial Statistics
Sales & Book Value
| Annual Sales: | $14.1M |
|---|---|
| Cash Flow: | $-12.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $4.11 |
| Price / Book: | 6.31 |
Profitability
| EPS (TTM): | -2.25000 |
|---|---|
| Net Income (TTM): | $-198.9M |
| Gross Margin: | -- |
| Return on Equity: | -51.66% |
| Return on Assets: | -46.22% |
NewAmsterdam Pharma Co NV Earnings Forecast
Key NewAmsterdam Pharma Co NV Financial Ratios
-
The Research & Development expenses have been 1,131.47% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of NAMS is -1,255.76% of Total Revenues.
-
Per Share Earnings over the last 4 years have been positive in 0 years.
NewAmsterdam Pharma Co NV Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | NAMS |
| Website: | newamsterdampharma.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 10.61 |
| Quick Ratio: | 10.37 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
NAMS Technical Analysis vs Fundamental Analysis
Sell
43
NewAmsterdam Pharma Co NV (NAMS)
is a Sell
Is NewAmsterdam Pharma Co NV a Buy or a Sell?
-
NewAmsterdam Pharma Co NV stock is rated a SellThe current NewAmsterdam Pharma Co NV [NAMS] share price is $25.86. The Score for NAMS is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.